Leucine

FDA 483 Insights Report

Hetero Labs, India (Sept 2025)

This report reflects Leucine's analysis and is shared for informational context only; it is not prescriptive

483 Risk Summary

Facility Name	Hetero Labs, Unit IX, India
Inspection Date	19-26 September, 2025
Subsystems Impacted	Batch Records, OOS/OOT, Document Management, Material Storage, and Control
Site History	Received 483 in November 2022

	Observation	Scope	Patient Severity	Risk of Escalation	Cost of Remediation
1	Use of Unregistered Testing Laboratory	Quality, Data Integrity	🔴	🔴	🔴
2	Undocumented Offsite Warehouse	Materials Control, Distribution	🔴	🔴	🟡
3	Discrepancies in Batch Records & Yields	Production, Documentation	🔴	🟡	🟡
4	Document Control Failures & Data Destruction	Quality Systems, Data Integrity	🔴	🔴	🔴
5	Label Reconciliation Failures	Packaging, Traceability	🟡	🟡	🟢
6	Uninvestigated OOS Results	Laboratory Controls, QA	🔴	🔴	🟡

Pratik Upadhyay's Profile 🟡

Inspections	483s	Recent 483s
89	67	Sun Pharma (Jun 2025), Alembic (May 2025), Micro Labs (Feb 2025), Shiva Analytics (Jan 2025), and others

483 Risk Summary

This section provides actionable insights into root cause and CAPA strategy, ensuring transparency, regulatory compliance, and continuous improvement

Observation 1

Use of Unregistered Testing Laboratory

Observation Description		Root Cause	CAPA Actions
1.1	APIs and intermediates intended for the US market were tested at an unregistered lab not listed in any DMF.	Lack of oversight and failure to control subcontracted testing operations	- Immediately cease testing at unregistered sites - Validate and register all third-party labs - Implement contractual quality agreements.
1.2	Original QC notebooks, signed CoAs, and validation records were found at the offsite location.	Inadequate document control and failure to enforce record retention protocols.	- Establish a central document repository with controlled access and an audit trail - Retrain QC staff on record ownership.
1.3	Hetero corporate IT records revealed procurement and correspondence with an unregistered lab under a code name.	Intentional circumvention of quality governance to expedite throughput.	- Initiate internal investigation and disciplinary action; enforce escalation matrix for any off-site analytical activity.

Observation 2

Undocumented Offsite Warehouse

Observation Description		Root Cause	CAPA Actions
2.1	APIs and intermediates were stored in an off-site warehouse with no receiving, inspection, or storage records.	Absence of procedural control and unapproved distribution practices.	- Register warehouse under corporate quality system - Document all stock movements in ERP with batch-level traceability.
2.2	No environmental monitoring or segregation	Lack of defined warehouse	- Perform facility qualification

483 Risk Summary

	of quarantined material was maintained.	qualification and monitoring plan.	- Install calibrated sensors for temperature/humidity - Establish monitoring SOPs
2.3	No quality approval for release or shipment to offsite warehouse.	QA oversight gaps and uncontrolled material flow.	- Implement QA release hold before dispatch - Conduct reconciliation audit of all stored drums.

Observation 3

Discrepancies in Batch Records and Yields

Observation Description		Root Cause	CAPA Actions
3.1	Batch records did not support the actual yield; undocumented surplus drums were found.	Inaccurate recording practices and possible duplicate or parallel manufacturing.	- Initiate full batch genealogy audit - Reconcile raw material usage to output - Validate MES implementation for yield tracking.
3.2	Extra drums beyond batch size found in undisclosed warehouse.	Weak in-process control and material reconciliation procedures.	- Introduce automated reconciliation (input–output) - Retrain production and QA teams on yield documentation.
3.3	Finished APIs released without verifying completeness of documentation.	Pressure for release timelines and inadequate QA review.	- Implement QA hold policy for incomplete documentation - Strengthen final batch review checklist.

.

483 Risk Summary

Observation 4

Document Control Failures & Data Destruction

Observation Description		Root Cause	CAPA Actions
4.1	GMP documents found torn and discarded in scrap bags.	Lack of data integrity awareness and document control enforcement.	- Enforce SOP CO-CQA-003 and CO-CQA-078 - Install locked document disposal bins with QA control.
4.2	Forged or backdated “Training Agreement” identified.	Deliberate falsification due to inadequate governance and document verification.	- Conduct forensic document review - Establish signature verification and digital approval systems.
4.3	Uncontrolled use of white papers for test data and subsequent destruction.	Non-compliance with ALCOA+ principles.	- Retrain all QC analysts - Enforce usage of bound, numbered lab notebooks - Periodic data integrity audits.

Observation 5

Label Reconciliation Failures

Observation Description		Root Cause	CAPA Actions
5.1	Labels issued for batches did not match actual production drums.	Absence of label reconciliation SOP and weak control on packaging inventory.	- Implement electronic label issuance and reconciliation system - QA verification required before release.
5.2	Duplicate batch labels found across warehouses.	Poor segregation and lack of real-time label tracking.	- Introduce barcode-based label management integrated with ERP - Perform retrospective reconciliation of all batches.

483 Risk Summary

Observation 6

Uninvestigated Out-of-Specification (OOS) Results

Observation Description		Root Cause	CAPA Actions
6.1	OOS results obtained at unregistered lab not documented in site OOS register.	Intentional omission and data manipulation to avoid re-testing delays.	- Conduct independent data verification - Update OOS procedure to require vendor result reconciliation.
6.2	Passing results recorded at Hetero IX despite known OOS outcomes externally.	QA failure to ensure data integrity across contracted sites.	- Cross-check analytical data with raw chromatograms - Perform 100% review of all OOS linked lots.

AI for FDA Compliant Pharma Manufacturing

Manufacturing	Quality	Contamination Control
Batch Execution AI-powered Batch Execution	**AI Investigator** Close Investigations Faster	**Environmental Monitoring** Plan/Track & analyze EM Samples
Batch Intelligence Deliver On-time In-Full	**QMS/DMS** Simplify Quality & Doc Managentent	**Cleaning Validation** FDA-ready Cleaning Validation
Production Logbook Integrate Production Logbooks	**FDA Tracker** Track 483/WL data	**Media Fill Simulation** Validate aseptic processing

Trusted by 350+ GMP Sites

Cipla · Piramal · Dr.Reddy's · onesource · amneal · VIATRIS · Biocon · LUPIN · torrent PHARMA

See AI-powered FDA-Compliance in Action

Bring your entire shopfloor into one integrated, FDA-compliant Environment

Click Here to Book a Demo or Scan the QR

Audit Checklist to prepare for Pratik Upadhyay

This section provides insights into the investigator's focus area and along with the audit checklist to follow in case the investigator visits the site.

Focus Area		CAPA Priority	Evidence Required	Preventive Actions
1	**Contamination Control**	Revise and enforce contamination control SOPs; retrain operators on aseptic practices.	Environmental monitoring logs; cleaning and sanitation records.	Implement enhanced EM schedules; conduct quarterly hygiene audits.
2	**Document Management**	Update document control procedures; ensure QA controlled issuance and destruction of GMP records.	Controlled copy logs; EDMS access reports; GDP training records.	Automate document version control; conduct periodic GDP compliance audits.
3	**Data Integrity**	Strengthen data review and audit trail checks; enforce ALCOA+ principles.	Audit trail reports; user access logs; data integrity training records.	Automate audit trail reviews; conduct quarterly data integrity assessments.
4	**Environmental Monitoring**	Revise EM plan to include all critical areas; ensure validated alert & action limits.	EM protocols; calibration records; trend analysis reports.	Digitize EM data tracking; retrain EM personnel on deviation response.
5	**Equipment Cleaning**	Update cleaning validation protocols; verify post-cleaning inspections.	Cleaning validation reports; swab test data; training records.	Schedule regular revalidation; perform quarterly cleaning audits.

Get Inspection Ready against this 483

This section helps in staying audit-ready for this particular 483's observations, along with recommended evidence.

Observation 1

Use of Unregistered Testing Laboratory

Questions		YES	NO	N/A	Recommended Evidence
1.1	Show registration and qualification records for all third-party testing labs.	☐	☐	☐	Approved vendor list; qualification and audit reports; quality agreements.
1.2	How do you ensure no testing is performed at unapproved sites?	☐	☐	☐	Sample tracking logs; QA authorization for external testing; vendor approval workflow.
1.3	How are test samples transferred, documented, and reconciled?	☐	☐	☐	Chain-of-custody logs; courier records; QA release notes.
1.4	How is data from external labs verified and archived?	☐	☐	☐	Raw data review records; COA cross-verification; electronic backup confirmation.
1.5	What training exists for employees on vendor oversight?	☐	☐	☐	Training matrix; competency assessment records; SOP on vendor QA oversight.

Get Inspection Ready against this 483

Observation 2

Undocumented Offsite Warehouse

Questions		YES	NO	N/A	Recommended Evidence
2.1	Show warehouse qualification and approval documentation.	☐	☐	☐	Facility qualification report; temperature-mapping data; QA approval note.
2.2	How is material traceability maintained between production and storage?	☐	☐	☐	ERP/stock movement logs; dispatch and receipt records; reconciliation sheets.
2.3	What controls monitor storage conditions?	☐	☐	☐	Temperature/humidity logs; calibration records; deviation reports.
2.4	How do you segregate quarantined and released material?	☐	☐	☐	Warehouse floor layout; material status labels; segregation SOP.
2.5	How is warehouse access controlled?	☐	☐	☐	Access logbook; CCTV audit; security roster.

Observation 3

Discrepancies in Batch Records and Yields

Questions		YES	NO	N/A	Recommended Evidence
3.1	How are yield calculations verified and documented?	☐	☐	☐	Batch production records; yield summary sheets; QA review forms.
3.2	Show reconciliation between raw materials used and output produced.	☐	☐	☐	Material issuance and return logs; ERP reconciliation reports.

Get Inspection Ready against this 483

3.3	How do you ensure batch records are complete before QA release?	☐	☐	☐	Completed BMR checklist; QA batch disposition form.
3.4	What actions were taken for extra drums or undocumented yields?	☐	☐	☐	Deviation reports; investigation summary; CAPA closure records.
3.5	How are production staff trained on documentation accuracy?	☐	☐	☐	Training logs; effectiveness test records.

Observation 4

Document Control Failures & Data Destruction

Questions		YES	NO	N/A	Recommended Evidence
4.1	What SOPs govern document issuance, storage, and destruction?	☐	☐	☐	SOP copies; current revision logs.
4.2	Show records of destroyed GMP documents and QA approvals.	☐	☐	☐	Destruction logs; QA authorization forms; shred vendor certificate.
4.3	How do you prevent uncontrolled use of blank/white papers?	☐	☐	☐	Controlled stationery issuance log; QA audit report.
4.4	How is training on GDP and data integrity conducted and tracked?	☐	☐	☐	Training completion matrix; attendance and test scores.
4.5	How do you ensure real-time documentation of test	☐	☐	☐	Lab notebook control logs; analyst raw data review records.

	data?				

Observation 5

Label Reconciliation Failures

Questions		YES	NO	N/A	Recommended Evidence
5.1	How are issued, used, and returned labels reconciled?	☐	☐	☐	Label issuance/return register; reconciliation sheet signed by QA.
5.2	What system prevents duplicate batch labeling?	☐	☐	☐	ERP/barcode label generation record; system access log.
5.3	Show label control SOP and destruction record of obsolete labels.	☐	☐	☐	Label control SOP; destruction log; QA approval.
5.4	How is label stock stored and secured?	☐	☐	☐	Label inventory log; access control record; CCTV snapshot if applicable.
5.5	How do you review label reconciliation before batch release?	☐	☐	☐	QA checklist; release approval form.

Observation 6

Uninvestigated Out-of-Specification (OOS) Results

Questions		YES	NO	N/A	Recommended Evidence
6.1	Show complete OOS investigation logs, including external lab data.	☐	☐	☐	OOS master log; investigation reports; vendor test data.

Get Inspection Ready against this 483

6.2	How are OOS results trended and escalated?	☐	☐	☐	OOS trend report; QA review meeting minutes.
6.3	How is data from external labs verified before lot release?	☐	☐	☐	Comparative COA review; QA release approval.
6.4	Were affected lots placed on stability or held from distribution?	☐	☐	☐	Stability inclusion log; QA hold memo; product disposition form.
6.5	What preventive measures were implemented after OOS?	☐	☐	☐	CAPA implementation records; effectiveness check reports.

Leucine

Trusted by 350+ Sites Globally

Dr.Reddy's Cipla Piramal

LUPIN onesource amneal

VIATRIS Biocon torrent PHARMA

Click here to request a personalized demo

Or send an email to **contact@leucinetech.com**